Granulocyte-monocyte/macrophage apheresis for steroid-nonresponsive or steroid-intolerant severe alcohol-associated hepatitis: A pilot study.
Ryosuke KasugaPo-Sung ChuNobuhiro NakamotoAya YoshidaRei MorikawaTakaya TabuchiFumie NoguchiKarin YamatakaYukie NakadaiMayuko KondoHirotoshi EbinumaTakanori KanaiNobuhiro NakamotoPublished in: Hepatology communications (2024)
Compared to published studies, GMA is associated with a lower-than-expected 90- and 180-day mortality in patients with CS-nonresponsive or CS-intolerant SAH. GMA may meet the needs as a salvage anti-inflammatory therapy for SAH. (Trial registration: UMIN000019351 and jRCTs No.032180221) (274 words).
Keyphrases
- anti inflammatory
- peripheral blood
- study protocol
- dendritic cells
- phase iii
- cardiovascular events
- adipose tissue
- clinical trial
- early onset
- endothelial cells
- phase ii
- case control
- risk factors
- alcohol consumption
- randomized controlled trial
- systematic review
- type diabetes
- cardiovascular disease
- open label
- recombinant human